IMA 201

Drug Profile

IMA 201

Alternative Names: IMA201 T-Cells

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immatics US
  • Developer Immatics US; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Head and neck cancer

Most Recent Events

  • 26 Sep 2017 Phase-I clinical trials in Head and neck cancer in USA (IV) (NCT03247309)
  • 16 Aug 2017 Immatics plans a phase I trial in Head and Neck cancer (NCT03247309)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top